Скачать или смотреть 🔥 Today’s NASDAQ BIOMEDICAL Stocks (December 8, 2025) 🔥

🧬 WVE, FULC, BDRX Stocks Surge on Massive Obesity & Rare Disease Breakthroughs! 📈
We break down the overwhelming clinical trial success, key medical conference data, and financial maneuvers driving these three colossal percentage gainers on the NASDAQ today. This is a monumental day for the biotech sector!

The numbers are:

Wave Life Sciences Ltd (WVE, NASDAQ): +147.26% (a gain of $11.03)

Biodexa Pharmaceuticals (BDRX, NASDAQ): +74.60% (a gain of $3.76)

Fulcrum Therapeutics Inc (FULC, NASDAQ): +45.96% (a gain of $4.09)

🔑 Why They're MOVING (High-Conviction Catalysts):
WVE is rocketing after reporting landmark Phase 1 data for WVE-007 (obesity treatment), showing significant visceral and total body fat reduction with a dosing advantage over GLP-1s, leading to a simultaneous $250 million equity offering.

FULC is surging on positive initial results from its Phase 1b PIONEER trial (pociredir) in Sickle Cell Disease, presented at the prestigious ASH Annual Meeting, confirming robust fetal hemoglobin induction.

BDRX is experiencing extreme volatility and momentum, fueled by high retail investor interest and continued speculation regarding its MTX110 brain cancer pipeline and specialized drug delivery technology.

WVE (Wave Life Sciences Ltd): The massive 147% surge is driven by extremely positive interim data from its Phase 1 INLIGHT trial of WVE-007, an investigational obesity treatment. A single dose showed significant improvements in body composition at three months, including a 9.4% reduction in visceral fat and a 4.5% reduction in total body fat, along with a 3.2% increase in lean mass. This data suggests potential competition to GLP-1 drugs with a potentially less frequent dosing schedule. The news is so strong that the company simultaneously announced a $250 million public offering to capitalize on the momentum, with the stock still surging on the net positive news.

FULC (Fulcrum Therapeutics Inc): The strong 45.96% gain is driven by positive data presented at the 67th American Society of Hematology (ASH) Annual Meeting over the weekend. Fulcrum announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in Sickle Cell Disease (SCD), which showed a robust mean increase in absolute fetal hemoglobin (HbF) and improved markers of hemolysis. This is a crucial validation for its lead program.

BDRX (Biodexa Pharmaceuticals PLC-ADR): The 74.60% jump in this low-float stock is primarily a strong momentum/volatility play. While no major clinical trial news was reported today, the stock is showing high technical momentum, possibly fueled by recent positive analyst attention (Zacks Rank #2, or Buy) and speculation regarding its MTX110 program for rare brain cancers and its proprietary Q-Sphera drug delivery technology.


WVE Wave Life Sci Ord Sh
GPCR Structure Therapeutics Inc
BDRX Biodexa Pharmaceuticals Plc ADR
ACXP Acurx Pharmaceuticals Inc
FULC Fulcrum Therapeutics Inc
MTVA Metavia Inc
KYMR Kymera Therapeutics Inc
TERN Terns Pharmaceuticals Inc
IMMP Immutep Ltd ADR
DBVT Dbv Technologies ADR
NRIX Nurix Therapeutics Inc
CGEM Cullinan Therapeutics Inc
LBRX Lb Pharmaceuticals Inc
VNDA Vanda Pharmaceuticals
PRME Prime Medicine Inc
YDES Yd Bio Limited
ARWR Arrowhead Pharma
CRDF Cardiff Oncology Inc
SNTI Senti Biosciences Inc
ONCO Onconetix Inc
CTNM Contineum Therapeutics Inc
CMMB Chemomab Therapeutics Ltd ADR
VTVT Vtv Theraptcs Cl A
CAMP Camp4 Therapeutics Corp
OKUR Onkure Therapeutics Inc
PRAX Praxis Precision Medicines Inc
DAWN Day One Biopharmaceuticals Inc
ANIX Anixa Biosciences Inc
CNSP Cns Pharmaceuticals Inc
BCTX Briacell Therapeutics Corp
PASG Passage Bio Inc
ALGS Aligos Therapeutics Inc
XCUR Exicure Inc
KOD Kodiak Sciences Inc
INMB Inmune Bio Inc
IVVD Invivyd Inc
TRDA Entrada Therapeutics Inc
STOK Stoke Therapeutics Inc
BTAI Bioxcel Therapeutics Inc
TENX Tenax Therapeutics
CRMD Cormedix Inc
KYTX Kyverna Therapeutics Inc
GLSI Greenwich Lifesciences Inc
TYRA Tyra Biosciences Inc
THAR Tharimmune Inc
ELTX Elicio Therapeutics Inc
RCKT Rocket Pharmaceuticals Inc
ABEO Abeona Therapeutics
MNMD Mind Medicine Mindmed Inc
IOVA Iovance Biotherapeutics Inc
BCYC Bicycle Therapeutics Plc ADR
ANNX Annexon Inc
INBX Inhibrx Biosciences Inc
ARVN Arvinas Inc
NNNN Anbio Biotechnology Cl A
ATRA Atara Biotherap

#Stocks #StockMarket #Investing #Finance #WVE #BDRX #FULC #Biotech #Pharma #NASDAQ #ObesityDrug #SickleCellDisease #ClinicalTrial #WVE007 #ASH2025 #YouTubeShorts